Galectin-9 suppresses the tumor growth of colon cancer in vitro and in vivo
暂无分享,去创建一个
T. Niki | A. Nishiyama | T. Masaki | Tomoko Tadokoro | A. Morishita | S. Fujihara | H. Iwama | Koji Fujita | K. Oura | J. Tani | T. Himoto | M. Hirashima | Taiga Chiyo | Mai Nakahara | Kei Takuma | Kei Nomura
[1] S. Ramalingam,et al. Regulation of microRNAs in Inflammation-Associated Colorectal Cancer: A Mechanistic Approach. , 2020, Endocrine, metabolic & immune disorders drug targets.
[2] M. Jin,et al. Galectin-3 not Galectin-9 as a candidate prognosis marker for hepatocellular carcinoma , 2020, PeerJ.
[3] Z. Zeng,et al. LncRNA AATBC regulates Pinin to promote metastasis in nasopharyngeal carcinoma , 2020, Molecular oncology.
[4] Suming Zhao,et al. miR-221-3p and miR-15b-5p promote cell proliferation and invasion by targeting Axin2 in liver cancer , 2019, Oncology letters.
[5] M. Aghaei,et al. Inhibition of didscoidin domain receptor 1 reduces epithelial–mesenchymal transition and induce cell‐cycle arrest and apoptosis in prostate cancer cell lines , 2019, Journal of cellular physiology.
[6] L. Varani,et al. The Tim-3-Galectin-9 Pathway and Its Regulatory Mechanisms in Human Breast Cancer , 2019, Front. Immunol..
[7] N. Ding,et al. Downregulation of microRNA-1246 inhibits tumor growth and promotes apoptosis of cervical cancer cells by targeting thrombospondin-2 , 2019, Oncology letters.
[8] S. Galiacy,et al. Targeting ALK in Cancer: Therapeutic Potential of Proapoptotic Peptides , 2019, Cancers.
[9] A. Jemal,et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.
[10] J. Meyerhardt,et al. NCCN Guidelines Insights: Colon Cancer, Version 2.2018. , 2018, Journal of the National Comprehensive Cancer Network : JNCCN.
[11] Meng Yang,et al. SIRT1 suppresses colorectal cancer metastasis by transcriptional repression of miR-15b-5p. , 2017, Cancer letters.
[12] Lei Cao,et al. MicroRNA-1246 inhibits cell invasion and epithelial mesenchymal transition process by targeting CXCR4 in lung cancer cells. , 2017, Cancer biomarkers : section A of Disease markers.
[13] Alan D. Lopez,et al. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study , 2017, JAMA oncology.
[14] S. Freels,et al. Adjuvant chemotherapy is associated with improved survival in patients with stage II colon cancer , 2016, Cancer.
[15] Y. Zhang,et al. Reduced Expression of Galectin-9 Contributes to a Poor Outcome in Colon Cancer by Inhibiting NK Cell Chemotaxis Partially through the Rho/ROCK1 Signaling Pathway , 2016, PloS one.
[16] T. Masaki,et al. Galectin-9 suppresses the proliferation of gastric cancer cells in vitro. , 2016, Oncology reports.
[17] T. Niki,et al. Galectin-9 suppresses cholangiocarcinoma cell proliferation by inducing apoptosis but not cell cycle arrest. , 2015, Oncology reports.
[18] C. Yu,et al. Defective Mismatch Repair Status was not Associated with DFS and OS in Stage II Colon Cancer Treated with Adjuvant Chemotherapy , 2015, Annals of Surgical Oncology.
[19] T. Niki,et al. Galectin-9 suppresses the growth of hepatocellular carcinoma via apoptosis in vitro and in vivo. , 2015, International journal of oncology.
[20] A. Griffioen,et al. Galectin expression in cancer diagnosis and prognosis: A systematic review. , 2015, Biochimica et biophysica acta.
[21] T. Masaki,et al. miRNA in hepatocellular carcinoma , 2015, Hepatology research : the official journal of the Japan Society of Hepatology.
[22] Q. Han,et al. MicroRNA-1246 enhances migration and invasion through CADM1 in hepatocellular carcinoma , 2014, BMC Cancer.
[23] Y. Yoshioka,et al. Eph receptor A10 has a potential as a target for a prostate cancer therapy. , 2014, Biochemical and biophysical research communications.
[24] T. Masaki,et al. Targeting receptor tyrosine kinases in gastric cancer. , 2014, World journal of gastroenterology.
[25] Yong Xia,et al. Helicobacter pylori and interleukin-8 in gastric cancer. , 2013, World journal of gastroenterology.
[26] R. Lothe,et al. Epigenetic and genetic features of 24 colon cancer cell lines , 2013, Oncogenesis.
[27] J. Meyerhardt,et al. Impact of age on the efficacy of newer adjuvant therapies in patients with stage II/III colon cancer: findings from the ACCENT database. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] J. Shaw,et al. Prospective of colon cancer treatments and scope for combinatorial approach to enhanced cancer cell apoptosis. , 2013, Critical reviews in oncology/hematology.
[29] W. Helfrich,et al. Therapeutic potential of Galectin‐9 in human disease , 2013, Medicinal research reviews.
[30] T. Azuma,et al. Predominant mucosal IL-8 mRNA expression in non-cagA Thais is risk for gastric cancer. , 2013, World journal of gastroenterology.
[31] T. Niki,et al. Galectin-9 in cancer therapy. , 2013, Recent patents on endocrine, metabolic & immune drug discovery.
[32] A. Haynes,et al. Association between adherence to National Comprehensive Cancer Network treatment guidelines and improved survival in patients with colon cancer , 2013, Cancer.
[33] N. Petrelli,et al. Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] J. D’Armiento,et al. The use of protein array to identify targetable receptor tyrosine kinases for treatment of human colon cancer. , 2010, International journal of oncology.
[35] R. Labianca,et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] T. Niki,et al. Galectin-9 suppresses tumor metastasis by blocking adhesion to endothelium and extracellular matrices. , 2008, Glycobiology.
[37] A. Yamauchi,et al. Galectin‐9, a Novel Prognostic Factor with Antimetastatic Potential in Breast Cancer , 2006, The breast journal.
[38] A. Yamauchi,et al. Galectin-9 as a Prognostic Factor with Antimetastatic Potential in Breast Cancer , 2005, Clinical Cancer Research.
[39] M. Hirashima,et al. Development of highly stable galectins: Truncation of the linker peptide confers protease‐resistance on tandem‐repeat type galectins , 2005, FEBS letters.
[40] H. Yoshiji,et al. Comparison study of the expressions of myristoylated alanine-rich C kinase substrate in hepatocellular carcinoma, liver cirrhosis, chronic hepatitis, and normal liver. , 2005, International journal of oncology.
[41] E. Lane,et al. Keratin 8/18 breakdown and reorganization during apoptosis. , 2004, Experimental cell research.
[42] H. Kim,et al. Relationship between Urokinase-Type Plasminogen Receptor, Interleukin-8 Gene Expression and Clinicopathological Features in Gastric Cancer , 2004, Oncology.
[43] G. Kramer,et al. Differentiation between Cell Death Modes Using Measurements of Different Soluble Forms of Extracellular Cytokeratin 18 , 2004, Cancer Research.
[44] C. Sessa,et al. The combination of yondelis and cisplatin is synergistic against human tumor xenografts. , 2003, European journal of cancer.
[45] M. Hirashima,et al. Association of Galectin-9 with Eosinophil Apoptosis , 2002, International Archives of Allergy and Immunology.
[46] M. Hirashima. Ecalectin/Galectin-9, a Novel Eosinophil Chemoattractant: Its Function and Production , 2000, International Archives of Allergy and Immunology.
[47] M. Hirashima,et al. Requirement of Divalent Galactoside-binding Activity of Ecalectin/Galectin-9 for Eosinophil Chemoattraction* , 2000, The Journal of Biological Chemistry.
[48] M. Hirashima,et al. Human Ecalectin, a Variant of Human Galectin-9, Is a Novel Eosinophil Chemoattractant Produced by T Lymphocytes* , 1998, The Journal of Biological Chemistry.
[49] M. M. Bradford. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.
[50] D. Broccoli,et al. Predictors of guideline treatment nonadherence and the impact on survival in patients with colorectal cancer. , 2015, Journal of the National Comprehensive Cancer Network : JNCCN.
[51] M. Ohkawa,et al. Selective eosinophil adhesion to fibroblast via IFN-gamma-induced galectin-9. , 2002, Journal of immunology.